Skip to content

EyePoint, Inc. EYPT Enterprise value

Enterprise value at other companies

Merck & Co. logo
Merck & Co.MRK
$341.11B+34.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.26B+40.8%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$2.21B+2,798%
HRO
HarrowHROW
$1.53B+13.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.83B-51.1%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Calculated from EyePoint, Inc. ’s reported figures.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's enterprise value?
EyePoint, Inc. (EYPT) reported enterprise value of $1.02B in Q1 2026.
How has EyePoint, Inc. 's enterprise value changed year-over-year?
EyePoint, Inc. 's enterprise value increased by 227.5% year-over-year, from $311.43M to $1.02B.
What is the long-term trend for EyePoint, Inc. 's enterprise value?
Over 5 years (2020 to 2025), EyePoint, Inc. 's enterprise value has grown at a 45.6% compound annual growth rate (CAGR), from $219.21M to $1.43B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.